AKT Inhibition in Solid Tumors With AKT1 Mutations

PURPOSE: AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary activity of AKT inhibition in AKT-mutant cancers. PATIENTS AND METHODS: Fifty-eig...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Hyman, David M., Smyth, Lillian M., Donoghue, Mark T.A., Westin, Shannon N., Bedard, Philippe L., Dean, Emma J., Bando, Hideaki, El-Khoueiry, Anthony B., Pérez-Fidalgo, José A., Mita, Alain, Schellens, Jan H.M., Chang, Matthew T., Reichel, Jonathan B., Bouvier, Nancy, Selcuklu, S. Duygu, Soumerai, Tara E., Torrisi, Jean, Erinjeri, Joseph P., Ambrose, Helen, Barrett, J. Carl, Dougherty, Brian, Foxley, Andrew, Lindemann, Justin P.O., McEwen, Robert, Pass, Martin, Schiavon, Gaia, Berger, Michael F., Chandarlapaty, Sarat, Solit, David B., Banerji, Udai, Baselga, José, Taylor, Barry S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501365/
https://ncbi.nlm.nih.gov/pubmed/28489509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.0143
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados